Hospira and Q Core Medical Sign International Distribution
Agreement for Sapphire Infusion System
LAKE FOREST, Ill., and PETACH
TIKVA, Israel, Jan. 22, 2013 /PRNewswire/ -- Hospira, Inc.
(NYSE: HSP), the world's leading provider of injectable drugs and
infusion technologies, and Q Core Medical, Ltd., an innovation
leader in infusion delivery systems, today announced that the
companies have entered into a distribution agreement for the Q Core
Sapphire™ multi-therapy infusion system. Through the arrangement,
Hospira will have exclusive rights to market and distribute
Sapphire -- a compact and lightweight infusion device system
frequently used in ambulatory and hospital settings -- in more than
60 key markets across Europe,
Asia and The Americas. The
agreement also enables Hospira to collaborate with Q Core for
distribution of its product development pipeline.
(Photo - http://photos.prnewswire.com/prnh/20130122/CG45348)
"Collaborating with Q Core reinforces Hospira's commitment to
providing advanced infusion systems that help improve the safety
and efficiency of I.V. (intravenous) medication administration,"
said Julie Sawyer Montgomery, vice
president, Medication Management Systems Marketing, Hospira. "With
clinicians in multiple regions using the Sapphire system to support
their medication administration needs, the device expands Hospira's
ability to help support patient safety in key geographies."
The Sapphire system satisfies a wide range of critical drug
delivery needs in ambulatory and hospital care environments and
readily adapts to emerging needs. It features a full-color
touch-screen and software designed to enable intuitive programming
and operation with minimal steps. The smart pump capabilities of
the Sapphire system help healthcare organizations support a high
level of medication delivery safety. The device is already in use
in Canada and Europe, and under regulatory review for
registrations in additional countries, including the United States.
"We see great synergy between our companies, combining our
advanced technology with Hospira's superb customer support,
technology, and global reach," said Dr. Boaz Eitan, CEO of Q Core Medical. "We believe
that the addition of our Sapphire brand into Hospira's portfolio
marks the beginning of a long-term and fruitful cooperation."
Adding the Sapphire system to the Hospira product portfolio
strengthens the breadth of the company's already comprehensive
medication management business. Hospira's current portfolio
features products such as Plum A+™ with Hospira MedNet™ safety
software, a proven and scalable advanced infusion pump system;
Symbiq™ infusion system with built-in Hospira MedNet, the first
general infusion system to require selection of an entry from the
safety software for all drug delivery programs; the market-leading
LifeCare PCA™ pain management pump with Hospira MedNet; and the
GemStar™ ambulatory infusion device. KLAS recognized Hospira as the
early leader in smart pump/EHR (electronic health record)
integration, with more live I.V. clinical integration sites than
any other infusion pump provider and the only vendor to integrate
with multiple EHR providers.1
Financial details of the agreement were not disclosed.
About Hospira
Hospira, Inc. is the world's leading
provider of injectable drugs and infusion technologies. Through its
broad, integrated portfolio, Hospira is uniquely positioned to
Advance Wellness™ by improving patient and caregiver safety while
reducing healthcare costs. The company is headquartered in
Lake Forest, Ill., and has
approximately 15,000 employees. Learn more at www.hospira.com.
About Q Core Medical
Q Core Medical is a dynamic,
expanding medical devices company focused on the ambulatory and
hospital based electronic infusion pump market. Q Core Medical
designs, develops, manufactures, and markets advanced pump systems
with multi-treatment I.V., enteral feeding, and veterinary
capabilities. Our world-class scientists and engineers are
committed to continuous research and development of new and
progressive products and technologies. Visit Q Core online at
www.qcore.com.
Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements about the distribution agreement between
Hospira and Q Core Medical. Hospira cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, legal, regulatory, technological, manufacturing
supply, quality and other factors that may affect Hospira's
operations and may cause actual results to be materially different
from expectations include the risks, uncertainties and factors
discussed under the headings "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" in Hospira's latest Annual Report on Form 10-K and
Forms 10-Q filed with the Securities and Exchange Commission, which
are incorporated by reference. Hospira undertakes no obligation to
release publicly any revisions to forward-looking statements as the
result of subsequent events or developments.
1"Smart Pumps 2012: Wireless Technology and EMR
Integration," April, 2012. © 2012 KLAS Enterprises, LLC. All rights
reserved. www.KLASresearch.com.
SOURCE Hospira, Inc.